From the Departments of Pediatrics (V.K.) and Neurology (R.S., S.R.K., V.G., B.H.), Klinikum rechts der Isar, Technische Universität, Munich; Department of Neuropediatrics (U.S., M.S.), Charité Universitätsmedizin, Berlin; Department of Pediatrics (M.S.), Hospital Augsburg, Germany; Department of Neuropediatrics (K.R.), University Hospital Innsbruck, Austria; Department of Pediatrics (S.L.), Hospital Dritter Orden, Munich; Department of Pediatric Surgery (S.H.), Städtisches Klinikum München GmbH, Klinikum Schwabing, Munich; and Munich Cluster for Systems Neurology (SyNergy) (B.H.), Munich, Germany.
Neurology. 2014 Feb 11;82(6):470-3. doi: 10.1212/WNL.0000000000000097. Epub 2014 Jan 10.
A serum antibody against the inward rectifying potassium channel KIR4.1 (KIR4.1-IgG) was recently discovered, which is found in almost half of adult patients with multiple sclerosis. We investigated the prevalence of KIR4.1-IgG in children with acquired demyelinating disease (ADD) of the CNS. We also compared antibody responses to KIR4.1 and myelin oligodendrocyte glycoproteins (MOGs), another potential autoantigen in childhood ADDs.
We measured KIR4.1-IgG by ELISA in children with ADD (n = 47), other neurologic disease (n = 22), and autoimmune disease (n = 22), and in healthy controls (HCs) (n = 18). One hundred six samples were also measured by capture ELISA. Binding of KIR4.1-IgG human subcortical white matter was analyzed by immunofluorescence. Anti-MOG antibodies were measured using a cell-based assay.
KIR4.1-IgG titers were significantly higher in children with ADD compared with all control groups by ELISA and capture ELISA (p < 0.0001, p < 0.0001). Overall, 27 of 47 patients with ADD (57.45%) but none of the 62 with other neurologic disease or autoimmune disease or the HCs (0%) were KIR4.1-IgG antibody positive by ELISA. Sera containing KIR4.1-IgG stained glial cells in brain tissue sections. No correlation among KIR4.1-IgG, age, or MOG-IgG was observed in the ADD group.
Serum antibodies to KIR4.1 are found in the majority of children with ADD but not in children with other diseases or in HCs. These findings suggest that KIR4.1 is an important target of autoantibodies in childhood ADD.
最近发现了一种针对内向整流钾通道 KIR4.1(KIR4.1-IgG)的血清抗体,这种抗体存在于近一半的多发性硬化症成年患者中。我们研究了中枢神经系统获得性脱髓鞘疾病(ADD)患儿中 KIR4.1-IgG 的患病率。我们还比较了针对 KIR4.1 和髓鞘少突胶质细胞糖蛋白(MOGs)的抗体反应,MOGs 是儿童 ADD 中的另一种潜在自身抗原。
我们通过酶联免疫吸附试验(ELISA)测量了 ADD 患儿(n=47)、其他神经系统疾病患儿(n=22)和自身免疫性疾病患儿(n=22)以及健康对照者(HCs)(n=18)血清中的 KIR4.1-IgG。106 个样本也通过捕获 ELISA 进行测量。通过免疫荧光分析 KIR4.1-IgG 与人皮质下白质的结合。使用基于细胞的测定法测量抗 MOG 抗体。
与所有对照组相比,通过 ELISA 和捕获 ELISA,ADD 患儿的 KIR4.1-IgG 滴度显著更高(p<0.0001,p<0.0001)。总体而言,47 名 ADD 患儿中有 27 名(57.45%)而 62 名其他神经系统疾病或自身免疫性疾病患儿或 HCs (0%)均为 ELISA 阳性。含 KIR4.1-IgG 的血清可使脑组织切片中的神经胶质细胞染色。在 ADD 组中,KIR4.1-IgG 与年龄或 MOG-IgG 之间没有相关性。
KIR4.1 的血清抗体存在于大多数 ADD 患儿中,但不存在于其他疾病患儿或 HCs 中。这些发现表明 KIR4.1 是儿童 ADD 中自身抗体的一个重要靶标。